Companies · Pharmaceuticals

Verseon Corp

FREMONT · Pharmaceuticals

Diligence memoA one-page analyst read on Verseon Corp — recommendation, valuation, rhythm, risks.
$24.9M
Total raised · real
6
Rounds
0.2×
Latest step-up
Top 32%
Sector rank · raised
Series A
Latest stage · inferred · Mon Mar 18 2019 00:00:00 GMT+0000 (Coordinated Universal Time)

Verseon Corp looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.02× the median modeled value of Series A Pharmaceuticals companies in 2019–2021 (76 peers) — value vs value, same stage and era.
Dormant
  • Last raise 7.3 yr ago; this sector typically re-raises about every 13 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharmaceuticals

Verseon Corp is one of 1610 Pharmaceuticals companies tracked from FREMONT. By capital raised it ranks mid-pack (ahead of 69% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
1
Investors (latest)
2019-03-18
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$125M$250M$375M$500MSeries A · 2005-10-31 Raised $6.5M (real) Modeled valuation $201M (est)$6.5M$201MSeries A2005Series A · 2008-02-20 Raised $5.8M (real) Modeled valuation $181M (est)$5.8M$181MSeries A2008Series A · 2009-09-16 Raised $12M (real) Modeled valuation $366M (est)$12M$366MSeries A2009Series A · 2010-09-30 Raised $260K (real) Modeled valuation $8.0M (est)$260K$8.0MSeries A2010Series A · 2014-11-10 Raised $451K (real) Modeled valuation $14M (est)$451K$14MSeries A2014Series A · 2019-03-18 Raised $101K (real) Modeled valuation $3.1M (est)$101K$3.1MSeries A2019+$5.8M+$12M+$260K+$451K+$101KCumulative $25M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$6.5M · 2005
Series A extension$5.8M · 2008
Series A extension$11.8M · 2009
Series A extension$260K · 2010
Series A extension$451K · 2014
Series A extension$101K · 2019

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 33%.

Modeled valuation trajectory
$3.1M
Base estimate est.
$116K
Conservative case
$17.1M
Upside case
$461K
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Series A · modeled $201.0M · 2005-10-312005Series A · modeled $180.6M · 2008-02-20Series A · modeled $365.7M · 2009-09-16Series A · modeled $8.0M · 2010-09-30Series A · modeled $14.0M · 2014-11-10Series A · modeled $3.1M · 2019-03-182019
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
46%
Survival probability
25% low · 63% high
1.57×/yr
Annual markup
1.97×/yr upside case
6.0 yr
Elapsed time used
7.3 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
32 mo
Avg between rounds
$1.9M/yr
Capital velocity
20.7 yr
On record since
2005
First round
6
Rounds on file
How it compares to the market

Benchmarked against 1610 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 3.1× above median
This company$24.9M
Sector median$8.1M
Latest round — vs other Series A rounds in sector (real $, this stage) 0.0× of median
This company$101K
Sector median$5.2M
Modeled value — vs sector median (estimate, all stages) 0.0× of median
This company$3.1M
Sector median$76.1M

Raised more than 69% of sector peers (real $). Modeled value above 6% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #76 of 76.

This companyCohort peer
$1.0M$10.0M$100.0M$1.0B$1.0M$10.0M$100.0MCapital raised (log)Xynomic Pharmaceuticals Holdings, Inc. · Series A Raised $15.0M · modeled $464.6M (est)Honest Globe Inc. · Series A Raised $15.0M · modeled $464.3M (est)Athenen Therapeutics, Inc. · Series A Raised $12.0M · modeled $371.7M (est)Zomedica Pharmaceuticals Corp. · Series A Raised $25.6M · modeled $371.7M (est)CerSci Therapeutics Inc. · Series A Raised $12.0M · modeled $371.7M (est)Rational Vaccines, Inc. · Series A Raised $27.8M · modeled $363.5M (est)Primmune Therapeutics, Inc. · Series A Raised $20.1M · modeled $349.8M (est)Ally Therapeutics, Inc. · Series A Raised $10.0M · modeled $309.7M (est)Solaris Pharma Corp · Series A Raised $23.4M · modeled $309.7M (est)Aytu Bioscience, Inc · Series A Raised $28.8M · modeled $309.7M (est)Avitide, Inc. · Series A Raised $40.9M · modeled $309.7M (est)PharmAbbie, Inc. · Series A Raised $15.0M · modeled $281.7M (est)Verseon Corp (this company) Raised $24.9M · modeled $3.1M (est)Verseon Corp
CompanyStageRaised · realValue · estvs peer med.
Xynomic Pharmaceuticals Holdings, Inc.Series A$15.0M$464.6M3.05×
Honest Globe Inc.Series A$15.0M$464.3M3.05×
Athenen Therapeutics, Inc.Series A$12.0M$371.7M2.44×
Zomedica Pharmaceuticals Corp.Series A$25.6M$371.7M2.44×
CerSci Therapeutics Inc.Series A$12.0M$371.7M2.44×
Rational Vaccines, Inc.Series A$27.8M$363.5M2.39×
Primmune Therapeutics, Inc.Series A$20.1M$349.8M2.30×
Ally Therapeutics, Inc.Series A$10.0M$309.7M2.03×
Solaris Pharma CorpSeries A$23.4M$309.7M2.03×
Aytu Bioscience, IncSeries A$28.8M$309.7M2.03×
Avitide, Inc.Series A$40.9M$309.7M2.03×
PharmAbbie, Inc.Series A$15.0M$281.7M1.85×
Verseon Corp this companySeries A$24.9M$3.1M0.02×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$6.5M2005-10-31$29.5M$201.0M85%
Series A$5.8M2008-02-20$26.5M$180.6M85%
Series A$11.8M2009-09-16$53.7M$365.7M85%
Series A$260K2010-09-30$1.2M$8.0M85%
Series A$451K2014-11-10$2.0M$14.0M85%
Series A$101K2019-03-18$461K$3.1M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$6.5M2005-10-31
    • First recorded raise — entered as Series A.
    • 22 investors on this round.
  2. Series A$5.8M2008-02-20
    • Raised again after 28 mo — slower than the ~13 mo sector norm.
    • Round roughly the size of the prior one.
    • 28 investors on this round.
  3. Series A$11.8M2009-09-16
    • Raised 19 mo later, in step with the ~13 mo sector norm.
    • Round 2.0× larger than the prior — scaling up.
    • 5 investors on this round.
  4. Series A$260K2010-09-30
    • Raised 12 mo later, in step with the ~13 mo sector norm.
    • Round 45.5× smaller than the prior — bridge or down round.
    • 13 investors on this round.
  5. Series A$451K2014-11-10
    • Raised again after 49 mo — slower than the ~13 mo sector norm.
    • Round 1.7× larger than the prior — scaling up.
    • 10 investors on this round.
  6. Series A$101K2019-03-18
    • Raised again after 52 mo — slower than the ~13 mo sector norm.
    • Round 4.4× smaller than the prior — bridge or down round.
    • 1 investor on this round.
Intelligence
2021 ~Q4
Modeled next raise · ~32mo cadence
$101K
Modeled next size est.range $101K$162K
0.2×
Last step-up
$1.9M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Thomas Hecht1 other2019-03
Adityo Prakash2005-10
David Kita2005-10
Eniko Fodor2005-10
Sangtae Kim2019-03
Registry & provenance

Verseon Corp is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1348948
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
SciSparc Ltd.PharmaceuticalsSeries A$25.3M$16.1Msame sector · same stage
Synedgen, Inc.PharmaceuticalsSeries A$24.3M$8.2Msame sector · same stage
Inspyr Therapeutics, Inc.PharmaceuticalsSeries A$25.6M$12.1Msame sector · same stage
Adamis Pharmaceuticals CorpPharmaceuticalsSeries A$23.4M$3.8Msame sector · same stage
NLS Pharmaceutics Ltd.PharmaceuticalsSeries A$27.2M$3.3Msame sector · same stage
Leafline Labs, LLCPharmaceuticalsSeries A$27.5M$4.6Msame sector · same stage
Sun BioPharma, Inc.PharmaceuticalsSeries A$22.3M$13.0Msame sector · same stage
DemeRx, Inc.PharmaceuticalsSeries A$28.7M$9.0Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Verseau Therapeutics, Inc.PharmaSeries A$133.2M81%
Bell Pharmacy Holdings, LLCPharmaceuticalsPre-Seed$2.2M80%
Lyric Pharmaceuticals Inc.PharmaceuticalsSeries B$910.8M80%
AION Healthspan, Inc.PharmaceuticalsSeed$28.5M80%
Lexicon Pharmaceuticals, Inc.PharmaceuticalsSeries D+$373.9M80%
Continuus Pharmaceuticals, Inc.PharmaceuticalsSeries A$154.9M79%
MedAvail Holdings, Inc.PharmaceuticalsSeries B$678.6M79%
IntelGenx Technologies Corp.PharmaceuticalsSeed$7.1M78%
Frequently asked
How much funding has Verseon Corp raised?
Verseon Corp has raised approximately $24.9M in disclosed capital across 6 recorded financing rounds, aggregated from public filings.
What is Verseon Corp's estimated valuation?
Provath's modeled valuation for Verseon Corp is approximately $3.1M (modeled range $116K–$17.1M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Verseon Corp at?
Verseon Corp's latest modeled financing stage is Series A. Its most recent recorded round closed around Mon Mar 18.
What does Verseon Corp do and where is it based?
Verseon Corp operates in the Pharmaceuticals sector, based in FREMONT.
Explore related

See where Verseon Corp sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Verseon Corp, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.